L3VLUP
ProSign in

RGEN · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RGENGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RGEN
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterRGENGILD
Q3 202011 holders, $1.1bn25 holders, $14.2bn
Q4 202011 holders, $1.6bn27 holders, $13.4bn
Q1 202113 holders, $1.4bn24 holders, $14.5bn
Q2 202113 holders, $1.5bn18 holders, $14.9bn
Q3 202112 holders, $2.0bn20 holders, $16.4bn
Q4 202114 holders, $1.9bn20 holders, $16.8bn
Q1 202210 holders, $1.5bn28 holders, $13.2bn
Q2 20228 holders, $1.8bn26 holders, $13.6bn
Q3 20229 holders, $1.7bn24 holders, $13.3bn
Q4 20229 holders, $1.7bn32 holders, $21.1bn
Q1 20238 holders, $1.6bn27 holders, $21.8bn
Q2 20236 holders, $1.1bn24 holders, $20.7bn
Q3 20237 holders, $1.6bn24 holders, $20.0bn
Q4 20238 holders, $1.6bn22 holders, $21.5bn
Q1 20248 holders, $1.5bn30 holders, $20.3bn
Q2 202410 holders, $959m28 holders, $18.5bn
Q3 202410 holders, $1.3bn29 holders, $24.2bn
Q4 202411 holders, $1.7bn28 holders, $25.9bn
Q1 202511 holders, $1.7bn33 holders, $32.0bn
Q2 202510 holders, $1.5bn27 holders, $30.9bn
Q3 202513 holders, $1.5bn23 holders, $29.4bn
Q4 202512 holders, $2.0bn25 holders, $34.3bn
Q1 20269 holders, $1.2bn25 holders, $38.5bn
Q2 202610 holders, $1.2bn26 holders, $34.2bn
RGEN

Repligen Corp

Holders
11
Reported value
$1.7bn
Buyers
7
Sellers
5

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
33
Reported value
$32.0bn
Buyers
21
Sellers
12

Breadth +9 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RGEN (4)

Artisan Partners LP, Polen Capital Management LLC, Two Sigma Investments LP, Walleye Capital LLC

Only GILD (26)

Acadian Asset Management LLC, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Verition Fund Management LLC, Voloridge Investment Management LLC, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →